Redeye views today’s press release from Acarix as a positive development, confirming new reimburseme...
While the Q3’24 report did not contain any particular surprises in terms of financials, it did provi...
Redeye initiates coverage of MedCap, a serial acquirer of niche life science SMEs that has posted st...
Ahead of Relais Q3 report, we maintain our estimates intact.
Redeye comments on BioInvent's Q3 report, which presented new data for the subcutaneous version of B...
Exel’s Q3 figures disappointed due to the continued demand softness, however EBIT has plenty of pote...
Redeye comments on Tessin’s Q3 results, which were weaker than expected.
Redeye provides an update following CLS’s Q3 2024 report.
Redeye returns following IRLAB's Q3 report and recent news in the company.
We expect Suominen to deliver another quarter of improving profitability, driven by increased volume...
Q3e: Germany continues to weigh, US expected to be stable Lowered estimates in Germany on prolonged ...
Q3e sales -7% y-o-y (-12% org.), adj. EBITA 5.4% (8.
Redeye resumes coverage of Nanologica following the announced outcome of its rights issue, which sec...
Enrad AB:s nettoomsättning på ca 8,0 MSEK under kv3 2024 överensstämde med vår prognos före rapporte...
Loihde’s Q3 beat our estimates, offset by expectations of a slower Q4.
